Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00965887 | Bioequivalence of Two Tablet Forms of MK0974 (0974-045) | PHASE1 | COMPLETED | 36 | — | — | Mar 1, 2008 | May 1, 2008 | Jul 7, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | MK0974 Ethanolate |
| 2 | ACTIVE_COMPARATOR | MK0974 Hydrate |
| Name | Type | Description |
|---|---|---|
| MK0974 Ethanolate formulation | DRUG | Single dose MK0974 280 mg tablet in one of two treatment periods |
| Comparator: MK0974 Hydrate formulation | DRUG | Single dose MK0974 280 mg tablet in one of two treatment periods |
Inclusion Criteria: * Subject is in good health * Subject is a non-smoker * Subject is willing to comply with the study restrictions Exclusion Criteria: * Subject has a history of stroke, chronic seizures, or major neurological disorder * Subject has a history of cancer * Subject is a nursing mot...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 15 | PHASE3 | Atogepant, Topiramate, Ubrogepant, MEDI0618 |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant, Rimegepant/BHV3000, Zavegepant, Various, Rimegepant for acute migraine treatment |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1, erenumab-aooe |
| Ki Health Partners. LLC | RVNC | 1 | — | Daxibotulinumtonix A |